Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Conditions
Keywords
Heart Failure, Self-Management, Behavioral Clinical Trial
Brief summary
This study will test whether a self-management (SM) intervention, compared to usual care, will reduce the risk for adverse clinical outcome in patients with mild to moderate heart failure.
Detailed description
BACKGROUND: Heart failure is a major disabling disease for American adults, affecting an estimated 4.9 million individuals. Heart failure is associated with enormous health care expenditures. This is because it is a progressive chronic condition that is characterized by disabling symptoms that limit independence and result in multiple hospitalizations and referrals to long-term care. The emergence of heart failure as a major public health problem is related to the unintended result of both an aging population and the success in reducing mortality from cardiovascular disease. Non-adherence to medications is a key problem in the treatment of heart failure, with adherence rates ranging from 20% to 90%. There is a clear need, therefore, to develop interventions that improve adherence in patients with heart failure. DESIGN NARRATIVE: This is a single-site, partially blinded, randomized clinical trial of 900 patients with systolic or diastolic dysfunction, and New York Heart Association (NYHA) functional class II or III. Patients will be recruited over a period of 2 years from seven hospitals. Patients will be randomly assigned to either a SM intervention or attention control. The SM group will meet 18 times for 2 hours over 1 year. These group sessions will teach patients how to use five basic self-management skills (self-monitoring, environmental restructuring, social support, cognitive restructuring, and the relaxation response) to help build self-efficacy and maintain it after the treatment has been discontinued. The attention control arm will consist of an educational intervention which includes 18 mailings of the American Heart Association Tip Sheets over the course of the first year, plus a telephone follow-up with the patient after each mailing to check receipt and comprehension of the Tip Sheet, and to address any questions about the Tip Sheet. Treatment effects will be evaluated using the primary outcome of hospitalization for heart failure or death, and the secondary outcomes of progression of heart failure, quality of life, and health care costs. Potential mediators of effectiveness will include improved adherence and improved psychosocial function.
Interventions
BEHAVIORALSelf-Management
18 in-person group sessions providing self-management training.
OTHERattention control
18 educational mailings follow by a a telephone call.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Lynda Powell, PhD, MEd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* NYHA classification of II or III * LVEF of 40% or less
Exclusion criteria
* Uncertain 12-month prognosis * Potential cardiac transplant within 1 year of study entry * Severe aortic stenosis * Uncontrolled ventricular tachycardia * Non-cardiac causes of heart failure symptoms (i.e., peripheral vascular disease, chronic obstructive pulmonary disease, and arthritis) * Major psychiatric co-morbidity * Unstable angina, myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 1 month prior to study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time until all-cause death or heart-failure hospitalization | Measured over the two years of study follow-up. | This is a composite outcome, measuring time from randomization to occurrence of death due to any cause or a hospitalization that is adjudicated to be due to heart-failure, among participants who experience either (or both) of these events. Only the first occurrence of either of these events is considered. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression of heart failure | Measured over the two years of study follow-up | Measured using change in NYHA Class and Six-Minute Walk distance, from baseline. |
| Quality of life | Measured over the two years of study follow-up | Measured using self-report heart-failure-specific quality of life scales. |
| Health care costs | Measured over the two years of study follow-up | — |
| Time until all-cause death or all-cause hospitalization | Measured over the two years of study follow-up | This is a composite outcome, measuring time from randomization to occurrence of death due to any cause or hospitalization for any reason, among participants who experience either (or both) of these events. Only the first occurrence of either of these events is considered. |
Countries
United States
Outcome results
None listed